Ameliorative Effect of Morinda Officinalis Oligosaccharides on LPS‐Induced Acute Lung Injury

• Published in: Chemistry & biodiversity Vol. 21; no. 5; pp. e202400506 - n/a
• Main Authors: Qing, Cheng, Wu, Yanrong, Liu, Binbin, Wang, Cheng, Zeng, Zhenguo
• Format: Journal Article
• Language: English
• Published: Switzerland Wiley Subscription Services, Inc 01.05.2024
• Subjects: Acute lung injury; Acute Lung Injury - chemically induced; Acute Lung Injury - drug therapy; Acute Lung Injury - metabolism; Acute Lung Injury - pathology; Animals; Biological activity; Cytokines - metabolism; Damage; Encyclopaedias; Genomes; Herbal medicine; Hsp90 protein; Inflammation; Lipopolysaccharides; Lipopolysaccharides - antagonists & inhibitors; Lipopolysaccharides - pharmacology; Lungs; Male; Medicinal plants; Mice; Mice, Inbred C57BL; Molecular docking; Molecular Docking Simulation; Morinda; Morinda - chemistry; Morinda officinalis oligosaccharides; Network pharmacology; NF-kappa B - metabolism; Oligosaccharides; Oligosaccharides - chemistry; Oligosaccharides - isolation & purification; Oligosaccharides - pharmacology; Pharmacology; Proteins; RAW 264.7 Cells; Traditional Chinese medicine; Acute lung injury; Morinda officinalis oligosaccharides; Network pharmacology; molecular docking
• ISSN: 1612-1872; 1612-1880
• DOI: 10.1002/cbdv.202400506

Acute lung injury (ALI) is a disease characterized by extensive lung damage and rampant inflammation, with a high mortality rate and no effective treatments available. Morinda officinalis oligosaccharides (MOOs), derived from the root of the traditional Chinese medicinal herb Morinda officinalis, known for its immune‐boosting properties, presents a novel therapeutic possibility. To date, the impact of MOOs on ALI has not been explored. Our study aimed to investigate the potential protective effects of MOOs against ALI and to uncover the underlying mechanisms through an integrated approach of network pharmacology, molecular docking, and experimental validation. We discovered that MOOs significantly mitigated the pathological damage and decreased the expression of pro‐inflammatory cytokines in LPS‐induced ALI in mice. Complementary in vitro studies further demonstrated that MOOs effectively attenuated the M1 polarization induced by LPS. Network pharmacology analysis identified HSP90AA1, HSP90AB1, and NF‐κB as key overlapping targets within a protein‐protein interaction (PPI) network. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses elucidated the biological processes and signaling pathways implicated in MOOs′ therapeutic action on ALI. Subsequently, molecular docking affirmed the binding of MOOs to the active sites of these identified targets. Corroborating these findings, our in vivo and in vitro experiments consistently demonstrated that MOOs significantly inhibited the LPS‐induced upregulation of HSP90 and NF‐κB. Collectively, these findings suggest that MOOs confer protection against ALI through a multi‐target, multi‐pathway mechanism, offering a promising new therapeutic strategy to mitigate this severe pulmonary condition.